The estimated Net Worth of David B Elsbree is at least $160 mil dollars as of 15 September 2023. Mr. Elsbree owns over 2,300 units of T2 Biosystems Inc stock worth over $17,995 and over the last 10 years he sold TTOO stock worth over $11,351. In addition, he makes $131,140 as Independent Director at T2 Biosystems Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Elsbree TTOO stock SEC Form 4 insiders trading
David has made over 17 trades of the T2 Biosystems Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 2,300 units of TTOO stock worth $5,290 on 15 September 2023.
The largest trade he's ever made was exercising 73,224 units of T2 Biosystems Inc stock on 25 June 2022 worth over $168,415. On average, David trades about 9,479 units every 119 days since 2014. As of 15 September 2023 he still owns at least 7,824 units of T2 Biosystems Inc stock.
You can see the complete history of Mr. Elsbree stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
David Elsbree biography
David B. Elsbree serves as Independent Director of the Company. He has served as a member of our Board of Directors since July 2014. From 1970 until 2004, Mr. Elsbree was employed by Deloitte & Touche, most recently as a senior partner. Mr. Elsbree served in a number of leadership roles in the firm’s high technology practice, including partner-in-charge of the New England High Technology Practice. Mr. Elsbree served on the board of directors of Art Technology Group, Inc. from June 2004 until January 2011 and on the board of directors of Acme Packet, Inc. from November 2006 until March 2013. Mr. Elsbree received his B.A. from Northeastern University. Mr. Elsbree’s extensive knowledge of and experience with technology companies and financial expertise contributed to our Board of Directors’ conclusion that he should serve as a director of our company.
What is the salary of David Elsbree?
As the Independent Director of T2 Biosystems Inc, the total compensation of David Elsbree at T2 Biosystems Inc is $131,140. There are 6 executives at T2 Biosystems Inc getting paid more, with John McDonough having the highest compensation of $1,637,480.
How old is David Elsbree?
David Elsbree is 73, he's been the Independent Director of T2 Biosystems Inc since 2014. There are 1 older and 17 younger executives at T2 Biosystems Inc. The oldest executive at T2 Biosystems Inc is John Cumming, 74, who is the Lead Independent Director.
What's David Elsbree's mailing address?
David's mailing address filed with the SEC is 101, Hartwell Avenue, Lexington, Middlesex County, Massachusetts, 02421, United States.
Insiders trading at T2 Biosystems Inc
Over the last 10 years, insiders at T2 Biosystems Inc have traded over $18,971,153 worth of T2 Biosystems Inc stock and bought 5,875,341 units worth $59,722,018 . The most active insiders traders include Adrian M Jones, Group L.P.Crg Partners Iii ..., eThomas J. Carella. On average, T2 Biosystems Inc executives and independent directors trade stock every 20 days with the average trade being worth of $764,499. The most recent stock trade was executed by John J Iii Sperzel on 24 February 2024, trading 67 units of TTOO stock currently worth $154.
What does T2 Biosystems Inc do?
t2 biosystems is developing innovative diagnostic products to improve patient health. with two fda-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, t2 biosystems is an emerging leader in the field of in vitro diagnostics. our initial development efforts target sepsis, hemostasis, bacteria and lyme disease, which are areas of significant unmet medical need. the company is utilizing its proprietary t2 magnetic resonance platform, or t2mr®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. at t2 biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. we invite you to apply for one of our open positions at www
What does T2 Biosystems Inc's logo look like?
Complete history of Mr. Elsbree stock trades at T2 Biosystems Inc
T2 Biosystems Inc executives and stock owners
T2 Biosystems Inc executives and other stock owners filed with the SEC include:
-
John McDonough,
Non-Executive Chairman of the Board -
Alec Barclay,
Chief Operating Officer -
John J. Sperzel III, B.Sc.,
Chairman & CEO -
Thomas Lowery,
Chief Scientific Officer -
Alec J. Barclay,
Chief Operations Officer -
Seymour Liebman,
Director -
David Elsbree,
Independent Director -
John Cumming,
Lead Independent Director -
Philip Taylor,
IR Contact Officer -
Robin Toft,
Independent Director -
Ninfa Saunders,
Independent Director -
Thierry Bernard,
Independent Director -
Anthony Pare,
Chief Commercial Officer -
Michael Gibbs,
Vice President, General Counsel -
John Sprague,
Chief Financial Officer -
John Sperzel,
President, Chief Executive Officer, Director -
Brett A. Giffin,
Chief Commercial Officer -
Dr. Aparna Jha Ahuja M.D.,
Chief Medical Officer -
Kelley J. Morgan,
Chief People Officer -
Michael Terrence Gibbs,
VP & Gen. Counsel -
John M. Sprague CPA,
Chief Financial Officer -
Aparna Ahuja,
Chief Medical Officer -
Brett A. Giffin,
Chief Commercial Officer -
Joanne Spadoro,
Chief Operations Officer -
Stanley Lapidus,
Director -
Rahul Dhanda,
SVP of Corporate Development -
Sachs Group Incgoldman Sach...,
-
Shawn Lynch,
Chief Financial Officer -
Joshua H. Bilenker,
Director -
David Harding,
Chief Commercial Officer -
Michael J. Cima,
Director -
Harry W Wilcox,
Director -
Group L.P.Crg Partners Iii ...,
-
Darlene M Deptula Hicks,
Chief Financial Officer -
Stanley N Lapidus,
Director -
Thomas J. Carella,
-
Michael A. Pfaller,
Chief Medical Officer -
Venture Partners V, L.P.Pol...,
-
Sarah O. Kalil,
Chief Operating Officer -
Maurice L Castonguay,
Chief Financial Officer -
Advisors, L.L.C. Mbd,
-
Venture Partners V, L.P.Pol...,
-
Sachs Group Incgoldman Sach...,
-
Alan L Crane,
Director -
Ventures Fund 2004 L P Flag...,
-
Capital Iii Lp Aisling Capi...,
-
Laura Lee Adams,
-
Adrian M Jones,
Director -
Sachs & Co. Llcgoldman Sach...,
-
Group L.P.Crg Partners Iii ...,